ELOX— Eloxx Pharmaceuticals, Inc.

$133M mkt cap

Metric	FY2025	FY2024	FY2023	FY2022
License and service revenue:	$0-100.0%	$6.4M	$0	—
Research and development	$3.1M-14.6%	$3.6M-58.4%	$8.6M-63.8%	$23.7M
General and administrative	$3.4M-35.6%	$5.3M-39.6%	$8.7M-18.7%	$10.7M
Total operating expenses	$6.4M-27.1%	$8.8M-48.9%	$17.3M-49.8%	$34.4M
Loss from operations	-$6.4M-160.9%	-$2.5M+85.7%	-$17.3M+49.8%	-$34.4M
Other (income) expense, net	-$443K-165.6%	$675K+388.5%	-$234K-114.2%	$1.6M
Net loss	-$6.0M-90.7%	-$3.1M+81.6%	-$17.1M+52.7%	-$36.1M
Net loss per share, basic	-$490.00+41.7%	-$840.00+87.3%	-$6630.00+60.2%	-$16650.00
Net loss per share, diluted	-$490.00+41.7%	-$840.00+87.3%	-$6630.00+60.2%	-$16650.00
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, basic	$12347495000.00+228.5%	$3758804000.00+46.2%	$2570620000.00+18.7%	$2166311000.00
Weighted average number of shares of common stock and pre-funded warrants used in computing net loss per share, diluted	$12347495000.00+228.5%	$3758804000.00+46.2%	$2570620000.00+18.7%	$2166311000.00

Source: SEC EDGAR XBRL. % change vs prior period shown where available.

Pro feature

Unlock 11 more years of annual history and full quarterly detail on Pro.

Source: SEC EDGAR 10-K and 10-Q filings. Last 4 years annual and quarterly free, full history (up to 20 years) on Pro.